Hologic released a statement confirming that the U.S. Preventive Services Task Force (USPSTF) draft guidelines for cervical cancer screening continue to support co-testing. This includes Hologic's cytology product and HPV test, which are key offerings in its diagnostics portfolio.
The clarification from Hologic addresses potential market uncertainty regarding the future of cervical cancer screening protocols. The continued support for co-testing is a positive development for the company's established diagnostic solutions.
Maintaining the recommendation for co-testing helps ensure the ongoing relevance and demand for Hologic's products in cervical cancer detection, providing stability for this segment of its business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.